Takeda Pharmaceutical Company Limited (4502.T) Latest Company News

Sep 2, 2026, 09:17 UTC
Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.
Source:
- nikkei.com
Aug 28, 2026, 21:39 UTC
The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.
Source:
Aug 25, 2026, 11:58 UTC
Takeda China announced a cooperation agreement with Ant Health on August 25, 2026, to explore digital technology applications in healthcare, including patient lifecycle management, physician digital empowerment, digital health ecosystem building, innovative payment models, and accelerating drug and new indication development.
Source:
- finance.sina.cn
Aug 24, 2026, 06:36 UTC
Takeda announced that Japan's Ministry of Health, Labour and Welfare approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults, making it the first and only medicine in Japan to address the underlying cause of the disease.
Source:
Aug 6, 2026, 02:20 UTC
Veritas In Silico ended its joint research collaboration with Takeda Pharmaceutical Company in April 2026 after achieving certain results and mutual discussions.
Source:
- s.kabutan.jp
Jul 30, 2026, 20:01 UTC
Keros Therapeutics will receive a $20 million development milestone payment from Takeda after the first patient was dosed in the ELRiSE MDS clinical trial.
Source:
- globenewswire.com
- zacks.com
Jul 30, 2026, 06:30 UTC
Takeda Pharmaceutical reported its fiscal Q1 (April-June 2026) consolidated net profit of 113.1 billion yen, down 8.9% year-on-year.
Source:
Jul 28, 2026, 09:59 UTC
Alembic Pharmaceuticals received final USFDA approval to market Prucalopride Tablets in 1 mg and 2 mg strengths in the United States.
Source:
- cnbctv18.com
Jul 17, 2026, 17:08 UTC
Takeda Pharmaceutical Co. Ltd. announced encouraging secondary data from two pivotal Phase 3 trials of its oral psoriasis drug zasocitinib.
Source:
- benzinga.com
Jul 15, 2026, 18:59 UTC
Insilico Medicine and Takeda Pharmaceutical signed a global strategic collaboration agreement with a total potential value of up to $600 million.
Source:
- wap.eastmoney.com
- finance.sina.cn
Jul 13, 2026, 08:18 UTC
Takeda Pharmaceutical announced on July 13, 2026 that it will open up to four plasma donation centers in Indonesia by 2027, with an initial investment of up to $30 million, marking its first such facility in ASEAN.
Source:
- nikkei.com
Jul 13, 2026, 03:50 UTC
Takeda Pharmaceutical Company Limited and the Indonesian Government announced a landmark collaboration to strengthen healthcare resilience and expand access to plasma-derived medicinal products, marked by a fractionation license granted to Takeda.
Source:
- marketscreener.com
- en.antaranews.com
Jul 2, 2026, 00:29 UTC
Insilico Medicine entered into a strategic collaboration with Takeda Pharmaceutical to discover AI-powered drug candidates, with total potential value up to $600 million.
Source:
Jun 11, 2026, 11:03 UTC
Takeda Pharmaceutical announced that its experimental once-daily psoriasis pill outperformed Bristol Myers Squibb's Sotyktu in a late-stage head-to-head trial.
Source:
- reuters.com
Jun 5, 2026, 07:54 UTC
Takeda Pharmaceutical recorded a $2.52 billion provision for antitrust litigation related to its constipation drug Amitiza, resulting in a net loss for the fiscal year ended March.
Source:
- marketscreener.com

4502.T

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.

The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.

Takeda announced that Japan's Ministry of Health, Labour and Welfare approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults, making it the first and only medicine in Japan to address the underlying cause of the disease.

Veritas In Silico ended its joint research collaboration with Takeda Pharmaceutical Company in April 2026 after achieving certain results and mutual discussions.

Keros Therapeutics will receive a $20 million development milestone payment from Takeda after the first patient was dosed in the ELRiSE MDS clinical trial.

Takeda Pharmaceutical reported its fiscal Q1 (April-June 2026) consolidated net profit of 113.1 billion yen, down 8.9% year-on-year.

Alembic Pharmaceuticals received final USFDA approval to market Prucalopride Tablets in 1 mg and 2 mg strengths in the United States.

Takeda Pharmaceutical Co. Ltd. announced encouraging secondary data from two pivotal Phase 3 trials of its oral psoriasis drug zasocitinib.

Insilico Medicine and Takeda Pharmaceutical signed a global strategic collaboration agreement with a total potential value of up to $600 million.

Takeda Pharmaceutical announced on July 13, 2026 that it will open up to four plasma donation centers in Indonesia by 2027, with an initial investment of up to $30 million, marking its first such facility in ASEAN.

Takeda Pharmaceutical Company Limited and the Indonesian Government announced a landmark collaboration to strengthen healthcare resilience and expand access to plasma-derived medicinal products, marked by a fractionation license granted to Takeda.

Insilico Medicine entered into a strategic collaboration with Takeda Pharmaceutical to discover AI-powered drug candidates, with total potential value up to $600 million.

Takeda Pharmaceutical announced that its experimental once-daily psoriasis pill outperformed Bristol Myers Squibb's Sotyktu in a late-stage head-to-head trial.

Takeda Pharmaceutical recorded a $2.52 billion provision for antitrust litigation related to its constipation drug Amitiza, resulting in a net loss for the fiscal year ended March.